Allergan plc (NYSE:AGN) Shares Sold by Timber Creek Capital Management LLC

Timber Creek Capital Management LLC trimmed its holdings in shares of Allergan plc (NYSE:AGN) by 78.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,772 shares of the company’s stock after selling 14,135 shares during the period. Timber Creek Capital Management LLC’s holdings in Allergan were worth $617,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Pacific Center for Financial Services boosted its position in Allergan by 1.3% during the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock worth $132,000 after acquiring an additional 7 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Allergan by 1.4% during the second quarter. Quadrant Capital Group LLC now owns 1,201 shares of the company’s stock worth $235,000 after acquiring an additional 16 shares during the last quarter. Ropes Wealth Advisors LLC boosted its position in Allergan by 5.2% during the second quarter. Ropes Wealth Advisors LLC now owns 605 shares of the company’s stock worth $147,000 after acquiring an additional 30 shares during the last quarter. WESPAC Advisors SoCal LLC boosted its position in Allergan by 1.6% during the second quarter. WESPAC Advisors SoCal LLC now owns 2,475 shares of the company’s stock worth $601,000 after acquiring an additional 38 shares during the last quarter. Finally, Auxier Asset Management boosted its position in Allergan by 0.6% during the second quarter. Auxier Asset Management now owns 8,010 shares of the company’s stock worth $1,947,000 after acquiring an additional 50 shares during the last quarter. 79.76% of the stock is owned by institutional investors and hedge funds.

In other news, Director Chris W. Bodine purchased 3,030 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were purchased at an average price of $164.77 per share, with a total value of $499,253.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider William Meury sold 11,807 shares of Allergan stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. Insiders have purchased a total of 17,630 shares of company stock worth $2,890,057 in the last 90 days. Company insiders own 0.36% of the company’s stock.

A number of analysts recently issued reports on the stock. Bank of America raised their target price on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Credit Suisse Group raised their target price on shares of Allergan from $214.00 to $215.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Leerink Swann raised their target price on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. ValuEngine lowered shares of Allergan from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald reiterated a “hold” rating and issued a $191.00 price target on shares of Allergan in a report on Tuesday, February 6th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have issued a buy rating to the stock. Allergan presently has a consensus rating of “Buy” and a consensus target price of $227.23.

Allergan plc (AGN) traded down $0.65 during trading hours on Thursday, hitting $165.98. 891,422 shares of the company traded hands, compared to its average volume of 3,092,310. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.88. The firm has a market cap of $55,420.00, a price-to-earnings ratio of -13.83, a price-to-earnings-growth ratio of 1.12 and a beta of 1.19. Allergan plc has a 1-year low of $156.00 and a 1-year high of $256.80.

Allergan (NYSE:AGN) last posted its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $4.74 by $0.12. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $3.90 EPS. equities research analysts forecast that Allergan plc will post 15.57 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be issued a dividend of $0.72 per share. This is a positive change from Allergan’s previous quarterly dividend of $0.70. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.74%. Allergan’s payout ratio is presently -23.35%.

ILLEGAL ACTIVITY NOTICE: “Allergan plc (NYSE:AGN) Shares Sold by Timber Creek Capital Management LLC” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://weekherald.com/2018/02/15/timber-creek-capital-management-llc-cuts-stake-in-allergan-plc-agn.html.

Allergan Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply